412 related articles for article (PubMed ID: 33036435)
1. Overcoming Barriers for siRNA Therapeutics: From Bench to Bedside.
Sajid MI; Moazzam M; Kato S; Yeseom Cho K; Tiwari RK
Pharmaceuticals (Basel); 2020 Oct; 13(10):. PubMed ID: 33036435
[TBL] [Abstract][Full Text] [Related]
2. Engineering siRNA therapeutics: challenges and strategies.
Ali Zaidi SS; Fatima F; Ali Zaidi SA; Zhou D; Deng W; Liu S
J Nanobiotechnology; 2023 Oct; 21(1):381. PubMed ID: 37848888
[TBL] [Abstract][Full Text] [Related]
3. Biotechnological Evolution of siRNA Molecules: From Bench Tool to the Refined Drug.
de Brito E Cunha D; Frederico ABT; Azamor T; Melgaço JG; da Costa Neves PC; Bom APDA; Tilli TM; Missailidis S
Pharmaceuticals (Basel); 2022 May; 15(5):. PubMed ID: 35631401
[TBL] [Abstract][Full Text] [Related]
4. The landscape of nanoparticle-based siRNA delivery and therapeutic development.
Moazzam M; Zhang M; Hussain A; Yu X; Huang J; Huang Y
Mol Ther; 2024 Feb; 32(2):284-312. PubMed ID: 38204162
[TBL] [Abstract][Full Text] [Related]
5. Strategies for improving the specificity of siRNAs for enhanced therapeutic potential.
Gatta AK; Hariharapura RC; Udupa N; Reddy MS; Josyula VR
Expert Opin Drug Discov; 2018 Aug; 13(8):709-725. PubMed ID: 29902093
[TBL] [Abstract][Full Text] [Related]
6. Delivery of RNAi Therapeutics to the Airways-From Bench to Bedside.
Qiu Y; Lam JK; Leung SW; Liang W
Molecules; 2016 Sep; 21(9):. PubMed ID: 27657028
[TBL] [Abstract][Full Text] [Related]
7. Lipid Nanoparticle Technology for Clinical Translation of siRNA Therapeutics.
Kulkarni JA; Witzigmann D; Chen S; Cullis PR; van der Meel R
Acc Chem Res; 2019 Sep; 52(9):2435-2444. PubMed ID: 31397996
[TBL] [Abstract][Full Text] [Related]
8. Chemical and structural modifications of RNAi therapeutics.
Ku SH; Jo SD; Lee YK; Kim K; Kim SH
Adv Drug Deliv Rev; 2016 Sep; 104():16-28. PubMed ID: 26549145
[TBL] [Abstract][Full Text] [Related]
9. Lipid and Polymer-Based Nanoparticle siRNA Delivery Systems for Cancer Therapy.
Mainini F; Eccles MR
Molecules; 2020 Jun; 25(11):. PubMed ID: 32532030
[TBL] [Abstract][Full Text] [Related]
10. Centyrin ligands for extrahepatic delivery of siRNA.
Klein D; Goldberg S; Theile CS; Dambra R; Haskell K; Kuhar E; Lin T; Parmar R; Manoharan M; Richter M; Wu M; Mendrola Zarazowski J; Jadhav V; Maier MA; Sepp-Lorenzino L; O'Neil K; Dudkin V
Mol Ther; 2021 Jun; 29(6):2053-2066. PubMed ID: 33601052
[TBL] [Abstract][Full Text] [Related]
11. Direct cytoplasmic delivery of RNAi therapeutics through a non-lysosomal pathway for enhanced gene therapy.
Zhou J; Zhang J; Chen S; Lin Q; Zhu R; Wang L; Chen X; Li J; Yang H
Acta Biomater; 2023 Oct; 170():401-414. PubMed ID: 37625679
[TBL] [Abstract][Full Text] [Related]
12. Nanoparticle-based delivery of small interfering RNA: challenges for cancer therapy.
Miele E; Spinelli GP; Miele E; Di Fabrizio E; Ferretti E; Tomao S; Gulino A
Int J Nanomedicine; 2012; 7():3637-57. PubMed ID: 22915840
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic Potency of Nanoformulations of siRNAs and shRNAs in Animal Models of Cancers.
Karim ME; Tha KK; Othman I; Borhan Uddin M; Chowdhury EH
Pharmaceutics; 2018 May; 10(2):. PubMed ID: 29861465
[TBL] [Abstract][Full Text] [Related]
14. Brain Targeting of siRNA via Intranasal Pathway.
Mohanty C; Kundu P; Sahoo SK
Curr Pharm Des; 2015; 21(31):4606-13. PubMed ID: 26486146
[TBL] [Abstract][Full Text] [Related]
15. Development of RNAi technology for targeted therapy--a track of siRNA based agents to RNAi therapeutics.
Zhou Y; Zhang C; Liang W
J Control Release; 2014 Nov; 193():270-81. PubMed ID: 24816071
[TBL] [Abstract][Full Text] [Related]
16. A role for peptides in overcoming endosomal entrapment in siRNA delivery - A focus on melittin.
Hou KK; Pan H; Schlesinger PH; Wickline SA
Biotechnol Adv; 2015 Nov; 33(6 Pt 1):931-40. PubMed ID: 26025036
[TBL] [Abstract][Full Text] [Related]
17. Chitosan layered gold nanorods as synergistic therapeutics for photothermal ablation and gene silencing in triple-negative breast cancer.
Yang Z; Liu T; Xie Y; Sun Z; Liu H; Lin J; Liu C; Mao ZW; Nie S
Acta Biomater; 2015 Oct; 25():194-204. PubMed ID: 26193000
[TBL] [Abstract][Full Text] [Related]
18. Small interfering RNA: Discovery, pharmacology and clinical development-An introductory review.
Ranasinghe P; Addison ML; Dear JW; Webb DJ
Br J Pharmacol; 2023 Nov; 180(21):2697-2720. PubMed ID: 36250252
[TBL] [Abstract][Full Text] [Related]
19. RNAi-Based Therapeutics and Novel RNA Bioengineering Technologies.
Traber GM; Yu AM
J Pharmacol Exp Ther; 2023 Jan; 384(1):133-154. PubMed ID: 35680378
[TBL] [Abstract][Full Text] [Related]
20. Subcellular fate and off-target effects of siRNA, shRNA, and miRNA.
Singh S; Narang AS; Mahato RI
Pharm Res; 2011 Dec; 28(12):2996-3015. PubMed ID: 22033880
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
